Timothy Hauser, MD
Critical Care Medicine · Dayton, OHNPI 1437386133
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,816 of the $3,883 with a category attached, or 72.5%. 25 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 29.3% of the total.
Across 149 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$1K
- AstraZeneca$620
- Regeneron Healthcare Solutions, Inc.$400
- GSK$375
- Sanofi$274
- Pulmonx Corporation$142
- plus $933 from 19 others
What the payments were for
- Travel & lodging$90823%
- Food & beverage$2,81673%
- Education$1584%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 4 | $1,139 |
| AstraZeneca | 27 | $620 |
| Regeneron Healthcare Solutions, Inc. | 17 | $400 |
| GSK | 28 | $375 |
| Sanofi | 20 | $274 |
| Pulmonx Corporation | 5 | $142 |
| Boehringer Ingelheim | 8 | $119 |
| Baxter Healthcare | 5 | $118 |
| United Therapeutics Corporation | 4 | $85 |
| Jazz Pharmaceuticals Inc. | 3 | $80 |
| Insmed, Inc. | 4 | $79 |
| Grifols USA, LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $42 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Inogen, Inc. | 2 | $36 |
| Pfizer | 2 | $33 |
| Amgen | 2 | $32 |
| Mylan Specialty L.p. | 2 | $31 |
| Abiomed | 1 | $27 |
| Verona Pharma, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $16 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,883 in reported general payments places this provider in the 85th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 13 | $166,785 |
| NucalaMepolizumab | 13 | $142,180 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 168 | $130,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 175 | $130,421 |
| Dupixent PenDupilumab | 17 | $61,979 |
| Spiriva RespimatTiotropium Bromide | 71 | $49,970 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $37,857 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $30,910 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $18,736 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $18,355 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $17,194 |
| DuleraMometasone/Formoterol | 18 | $6,966 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 251 | $5,520 |
| Fluticasone Propionate HfaFluticasone Propionate | 16 | $4,029 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $375 | $329,252309 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $119 | $254,613150 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $620 | $148,032210 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Dayton
- Andrea QuickDayton$1K
- Neal ChaissonCleveland$428K
- Robert SchilzCleveland$356K
- Nicholas PastisColumbus$145K
- Michael EssandohColumbus$135K
- Chiedozie UdehCleveland$24K
- Kari GorderColumbus$20K
- Elliott CrouserColumbus$16K
- Sadia BenzaquenCincinnati$15K
- Lawrence GoldsteinBoardman$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.